Biocompounds Pharmaceutical Inc. successfully passed the annual acceptance of Shanghai Science and Technology "little giant" cultivation enterprise.

Recently, the Shanghai Municipal Commission of science and technology and the Shanghai Municipal Commission of economy and information technology announced the acceptance evaluation results of Shanghai Science and Technology giant (including cultivation) enterprises in 2018. According to the implementation measures of Shanghai Science and Technology little giant project and the notice on carrying out the acceptance and evaluation of Shanghai Science and Technology little giant (including cultivation) enterprises in 2018, Biocompounds Pharmaceutical Inc.passed the annual acceptance of Shanghai Science and Technology "little giant" cultivation enterprises after independent application, acceptance and evaluation.

During the cultivation project period, BPI completed various tasks such as the optimization of innovation environment, the construction of R&D team and the R&D of scientific research projects, and carried out the upgrading and transformation of R&D laboratory and pilot test platform, environmental assessment filing and supporting environmental protection treatment facilities.

In order to promote the independent innovation of enterprises, improve the core competitiveness of enterprises, enhance the competitive advantages of enterprises in domestic and foreign industries, and speed up the construction of scientific and technological innovation, BPI applied for the scientific and technological "little giant" cultivation project of Shanghai "scientific and technological innovation action plan" in 2016 and was approved. It became a member of 87 "little giant" cultivation enterprises in Shanghai in that year, and the implementation period of the project is 2 years.

During the period of the little giant cultivation project, BPI completed the re identification of Shanghai high-tech enterprises and the identification of Songjiang District Enterprise Technology Center. It was evaluated as excellent in Songjiang District Enterprise Technology Center. It has also passed the certification of Shanghai academician expert workstation and the acceptance of Shanghai Patent Work pilot enterprises. BPI has obtained 4 invention patents, applied for 12 invention patents, 2 registered trademarks, formulated 4 enterprise standards and 22 product test reports. In 2017, Songjiang district industry university research innovation project was approved and completed the predetermined indicators of the project.

Tinib drugs and intermediates of past generations of non-small cell lung cancer (NSCLC) are the dominant varieties of BPI. In order to improve the existing tinib product line and consolidate the economic benefits and market share of such products, BPI has conducted research and development on the latest generation of API intermediates such as cabozantinib and ceritinib, which are hot spots in preclinical research and development of generic drugs, It also focuses on the industrialization pilot test and scale-up of intermediate production processes of palbociclib and gefitinib, and in-depth quality research and factory industrialization practice. In addition, BPI has vigorously expanded the industrialization of pioglitazone, as well as the development of other active products such as palcitol and other products.